Nitric oxide system and diabetic nephropathy

Diabetology & Metabolic Syndrome

Luis Henrique Canani¹  Rogério Friedman¹  Cristiane Bauermann Leitão¹  Bruno Schmidt Dellamea² 

[1] Endocrine Division of Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil;Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

关键词: T786C;    4b/a;    G894T;    NOS-3;    eNOS;    Polymorphism;    Diabetic nephropathy;    Diabetes;   

Others  :  805372
DOI  :  10.1186/1758-5996-6-17

 received in 2013-08-26, accepted in 2014-02-04,  发布年份 2014

【 摘 要 】

About 30% of patients with type 2 diabetes mellitus develop clinically overt nephropathy. Hyperglycemia is necessary, but not sufficient, to cause the renal damage that leads to kidney failure. Diabetic nephropathy (DN) is a multifactorial disorder that results from interaction between environmental and genetic factors. In the present article we will review the role of the nitric oxide synthase (NOS) in the pathogenesis of DN.

Nitric oxide (NO) is a short-lived gaseous lipophilic molecule produced in almost all tissues, and it has three distinct genes that encode three NOS isoforms: neuronal (nNOS), inducible (iNOS) and endothelial (eNOS).

The correct function of the endothelium depends on NO, participating in hemostasis control, vascular tone regulation, proliferation of vascular smooth muscle cells and blood pressure homeostasis, among other features. In the kidney, NO plays many different roles, including control of renal and glomerular hemodynamics. The net effect of NO in the kidney is to promote natriuresis and diuresis, along with renal adaptation to dietary salt intake.

The eNOS gene has been considered a potential candidate gene for DN susceptibility. Three polymorphisms have been extensively researched: G894T missense mutation (rs1799983), a 27-bp repeat in intron 4, and the T786C single nucleotide polymorphism (SNP) in the promoter (rs2070744). However, the potential link between eNOS gene variants and the induction and progression of DN yielded contradictory results in the literature.

In conclusion, NOS seems to be involve in the development and progression of DN. Despite the discrepant results of many studies, the eNOS gene is also a good candidate gene for DN.

【 授权许可】

   
2014 Dellamea et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Zelmanovitz T, Gerchman F, Balthazar APS, Thomazelli FCS, Matos JD, Canani LH: Diabetic nephropathy. Diabetol Metab Syndr 2009, 1(1):10. BioMed Central Full Text
• [2]Grudden G, Viberti G: Pathogenesis of Diabetic Nephropathy. In Joslin’s Diabetes Mellitus. Fourteenth Edition edition. Edited by Kahn CR. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:p. 853-866.
• [3]Carpena MP, Rados DV, Sortica DA, Souza BM, Reis AF, Canani LH, Crispim D: Genetics of diabetic nephropathy. Arq Bras Endocrinol Metabol 2010, 54(3):253-261.
• [4]Williams ME, Stanton RC: Management of Diabetic Kidney Disease. In Joslin’s Diabetes Mellitus. Fourteenth Edition edition. Edited by Kahn R. Philadelphia, PA: Lippincot Williams & Wilkins; 2005.
• [5]Gross JL, Silveiro SP, Canani LH, Friedman R, Leitão CB, Azevedo MJ: [Diabetic nephropathy and cardiac disease]. Arq Bras Endocrinol Metabol 2007, 51(2):244-256.
• [6]Murussi MA, Coester JL, Gross SP S: Diabetic nephropathy in type 2 diabetes mellitus. Arq Bras de Endocr Metabol 2003, 47(3):207-219.
• [7]Murussi M, Murussi N, Campagnolo N, Silveiro SP: [Early detection of diabetic nephropathy]. Arq Bras Endocrinol Metabol 2008, 52(3):442-451.
• [8]Bredt DS, Snyder SH: Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994, 63:175-195.
• [9]Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43(2):109-142.
• [10]Tsutsui M, Shimokawa H, Otsuji Y, Ueta Y, Sasaguri Y, Yanagiraha N: Nitric oxide synthases and cardiovascular diseases: insights from genetically modified mice. Circ J 2009, 73(6):986-993.
• [11]Rippin JD, Patel A, Belyaev ND, Gill GV, Barnett AH, Bain SC: Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia 2003, 46(3):426-428.
• [12]Chatterjee A, Black SM, Catravas JD: Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul Pharmacol 2008, 49(4–6):134-140.
• [13]Sato I, Morita I, Kaji K, Ikeda M, Nagao M, Murota S: Reduction of nitric oxide producing activity associated with in vitro aging in cultured human umbilical vein endothelial cell. Biochem Biophys Res Commun 1993, 195(2):1070-1076.
• [14]Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323(1):27-36.
• [15]Napoli C, Ignarro LJ: Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res 2009, 32(8):1103-1108.
• [16]Huang PL: eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009, 20(6):295-302.
• [17]Zanatta CM, Canani LH, Silveiro SP, Burttet L, Nabinger G, Gross JL: [Endothelin system function in diabetic nephropathy]. Arq Bras Endocrinol Metabol 2008, 52(4):581-588.
• [18]Yu Q, Gao F, Ma XL: Insulin says NO to cardiovascular disease. Cardiovasc Res 2011, 89(3):516-524.
• [19]Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, Thorens B, Scherrer U: Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly 2003, 133(25–26):360-363.
• [20]Pieper GM: Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 1999, 42(2):204-213.
• [21]Gonzalez-Sanchez JL, Martinez-Larrada MT, Sáez ME, Zabena C, Martínez-Calatrava MJ, Serrano-Rios M: Endothelial nitric oxide synthase haplotypes are associated with features of metabolic syndrome. Clin Chem 2007, 53(1):91-97.
• [22]Fernandez ML, Ruiz R, Gonzalez MA, Ramirez-Lorca R, Couto C, Ramos A, Gutierrez-Tous R, Rivera JM, Ruiz A, Real LM, Grilo A: Association of NOS3 gene with metabolic syndrome in hypertensive patients. Thromb Haemost 2004, 92(2):413-418.
• [23]Monti LD, Barlassina C, Citterio L, Galluccio E, Berzuini C, Setola E, Valsecchi G, Lucoti P, Pozza G, Bernardinelli L, Casari G, Piatti P: Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes 2003, 52(5):1270-1275.
• [24]Hsieh MC, Hsiao JY, Tien KJ, Chang SJ, Lin PC, Hsu SC, Liang HT, Chen HC, Lin SR: The association of endothelial nitric oxide synthase G894T polymorphism with C-reactive protein level and metabolic syndrome in a Chinese study group. Metabolism 2008, 57(8):1125-1129.
• [25]Imamura A, Takahashi R, Murakami R, Kataoka H, Cheng XW, Numaguchi Y, Murohara T, Okumura K: The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels. Eur J Endocrinol 2008, 158(2):189-195.
• [26]Piccoli JC, Gottlieb MGV, Castro L, Bodanese LC, Manenti ERF, Bogo MR, Peres A, Rocha MIUM, Cruz IBM: Association between 894G > T endothelial nitric oxide synthase gene polymorphisms and metabolic syndrome. Arq Bras Endocrinol Metabol 2008, 52(8):1367-1373.
• [27]Mount PF, Power DA: Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol (Oxf) 2006, 187(4):433-446.
• [28]Zoccali C: The endothelium as a target in renal diseases. J Nephrol 2007, 20(Suppl 12):S39-S44.
• [29]Lahera V, Salom MG, Miranda-Guardiola F, Moncada S, Romero JC: Effects of NG-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol 1991, 261(6 Pt 2):F1033-F1037.
• [30]Shultz PJ, Tolins JP: Adaptation to increased dietary salt intake in the rat. Role of endogenous nitric oxide. J Clin Invest 1993, 91(2):642-650.
• [31]Welch WJ, Wilcox CS: Macula densa arginine delivery and uptake in the rat regulates glomerular capillary pressure. Effects of salt intake. J Clin Invest 1997, 100(9):2235-2242.
• [32]Hall CN, Garthwaite J: What is the real physiological NO concentration in vivo? Nitric Oxide 2009, 21(2):92-103.
• [33]Baylis C: Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 2008, 294(1):F1-F9.
• [34]Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kejaschki D, Schreiner GF, Johnson RJ: Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002, 13(3):806-816.
• [35]Fliser D: Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. J Nephrol 2010, 23(4):369-376.
• [36]Nakagawa T, Segal M, Croker B, Johnson RJ: A breakthrough in diabetic nephropathy: the role of endothelial dysfunction. Nephrol Dial Transplant 2007, 22(10):2775-2777.
• [37]Valiatti FB, Crispim D, Benfica C, Valiati BB, Kramer CK, Canani LH: [The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy]. Arq Bras Endocrinol Metabol 2011, 55(2):106-113.
• [38]Nakagawa T: A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism. Clin Nephrol 2009, 71(2):103-109.
• [39]Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yazuka Y, Atkinson MA, Johnson RJ, Croker B: Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007, 18(2):539-550.
• [40]Tian XY, Wang WT, Xu A, Lu Y, Zhang Y, Wang L, Cheang WS, Wang Y, Yao X, Huang Y: Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res 2012, 110(9):1211-1216.
• [41]Souza BM, Assmann TS, Kliemann LM, Gross JL, Canani LH, Crispim D: The role of uncoupling protein 2 (UCP2) on the development of type 2 diabetes mellitus and its chronic complications. Arq Bras Endocrinol Metabol 2011, 55(4):239-248.
• [42]Prabhakar SS: Role of nitric oxide in diabetic nephropathy. Semin Nephrol 2004, 24(4):333-344.
• [43]Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, Pollock JS, Carmines PK: Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 2001, 12(8):1630-1639.
• [44]Komers R, Anderson S: Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 2003, 284(6):F1121-F1137.
• [45]Giacco F, Brownlee M: Oxidative stress and diabetic complications. Circ Res 2010, 107(9):1058-1070.
• [46]Arya A, Yadav HN, Sharma PL: Involvement of vascular endothelial nitric oxide synthase in development of experimental diabetic nephropathy in rats. Mol Cell Biochem 2011, 354(1–2):57-66.
• [47]Katyal T, Garg A, Budhiraja RD: Combination of daidzein, hemin and bms182874 halts the progression of diabetes-induced experimental nephropathy. Endocr Metab Immune Disord Drug Targets 2013, 13(2):152-162.
• [48]Brosius FC 3rd: New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 2008, 9(4):245-254.
• [49]Ksiazek P, Wojewoda P, Muc K, Buraczynska M: Endothelial nitric oxide synthase gene intron 4 polymorphism in type 2 diabetes mellitus. Mol Diagn 2003, 7(2):119-123.
• [50]Liu Y, Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Rich SS, Bowden DW, Freedman BI: T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study. J Am Soc Nephrol 2005, 16(4):1085-1090.
• [51]Ezzidi I, Mtiraoui N, Mohamed MBH, Mahjoub T, Kacem M, Almawi WY: Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786 T > C gene variants with diabetic nephropathy. J Diabetes Complications 2008, 22(5):331-338.
• [52]Buraczynska M, Ksiasek P, Zaluska W, Nowicka T, Ksiasek A: Endothelial nitric oxide synthase gene intron 4 polymorphism in patients with end-stage renal disease. Nephrol Dial Transplant 2004, 19(9):2302-2306.
• [53]Neugebauer S, Baba T, Watanabe T: Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000, 49(3):500-503.
• [54]Mollsten A, Lajer M, Jorsal A, Tarnow L: The endothelial nitri oxide synthase gene and risk pf diabetic nephropathy and development of cardiovascular disease in type 1 diabetes. Mol Genet Metab 2009, 97:5.
• [55]Tiwari AK, Prasad P, Thelma BK, Kumar KMP, Ammini AC, Gupta A, Gupta R: Oxidative stress pathway genes and chronic renal insufficiency in Asian Indians with Type 2 diabetes. J Diabetes Complications 2009, 23(2):102-111.
• [56]Taniwaki H, Ishimura E, Matsumoto N, Emoto M, Inaba M, Nishizawa Y: Relations between ACE gene and ecNOS gene polymorphisms and resistive index in type 2 diabetic patients with nephropathy. Diabetes Care 2001, 24(9):1653-1660.
• [57]Zintzaras E, Papathanasiou AA, Stefanidis I: Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: a HuGE review and meta-analysis. Genet Med 2009, 11(10):695-706.
• [58]Zeng Z, Li L, Zhang Z, Li Y, Wei Z, Huang K, He L, Shi Y: A meta-analysis of three polymorphisms in the endothelial nitric oxide synthase gene (NOS3) and their effect on the risk of diabetic nephropathy. Hum Genet 2010, 127(4):373-381.
• [59]Noiri E, Satou H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, Nishijima S, Yokomizo T, Tokunaga K, Fujita T: Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 2002, 40(4):535-540.
• [60]Thaha M, Pranawa M, Yogiantoro , Sutjipto , Sunarjo , Tanimoto M, Gohda T, Tomino Y: Association of endothelial nitric oxide synthase Glu298Asp polymorphism with end-stage renal disease. Clin Nephrol 2008, 70(2):144-154.
• [61]Suzuki H, Nagase S, Kikuchi S, Wang Y, Koyama A: Association of a missense Glu298Asp mutation of the endothelial nitric oxide synthase gene with end stage renal disease. Clin Chem 2000, 46(11):1858-1860.
• [62]Bellini MH, Figueira MN, Piccoli MF, Marumo JT, Cendoroglo MS, Neto MC, Dalboni MA, Batista MC, Goes MA, Schor N: Association of endothelial nitric oxide synthase gene intron 4 polymorphism with end-stage renal disease. Nephrology (Carlton) 2007, 12(3):289-293.
• [63]Mamoulakis D, Bitsori M, Galanakis E, Vazgiourakis V, Panierakis C, Gouliemos GN: Intron 4 polymorphism of the endothelial nitric oxide synthase eNOS gene and early microangiopathy in type 1 diabetes. Int J Immunogenet 2009, 36(3):153-157.
• [64]Shestakova MV, Vukolova OK, Gorashko NM, Voronko OE, Balbunova NB, Nosikov VV, Dedov IJ: The relationship between genetic and haemodynamic factgors in diabetic nephropathy (DN): case–control study in type 1 diabetes mellitus (T1DM). Diabetes Res Clin Pract 2006, 74:10.
• [65]Zanchi A, Mozulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS: Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000, 57(2):405-413.
• [66]Rahimi Z, Vaisi-Raygani A, Parsian A: Concomitant presence of endothelial nitric oxide 894 T and angiotensin II-converting enzyme D alleles are associated with diabetic nephropathy in a Kurdish population from Western Iran. Nephrology (Carlton) 2012, 17(2):175-181.
• [67]Jafari Y, Rahimi Z, Vaisi-Raygani A, Rezael M: Interaction of eNOS polymorphism with MTHFR variants increase the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients. Mol Cell Biochem 2011, 353(1–2):23-34.
• [68]Mollsten A, Vessman M, Svensson M, Forsblom C, Parkkonen M, Brismar K, Groop P, Dahiquist G: Glu298Asp and NOS4ab polymorphisms in diabetic nephropathy. Ann Med 2006, 38(7):522-528.
• [69]El-Din Bessa SS, Hamdy SM: Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients. Ren Fail 2011, 33(9):878-884.
• [70]Nagase S, Suzuki H, Wang Y, Kikuchi S, Hirayama A, Ueda A, Takada K, Oteki T, Obara M, Aoyagi K, Koyama A: Association of ecNOS gene polymorphisms with end stage renal diseases. Mol Cell Biochem 2003, 244(1–2):113-118.
• [71]Asakimori YN, Yorika Y, Taniguchi T, Ito S, Ogata Y, Kyuden N, Kohno T: (-786) C polymorphism of the endothelial nitric oxide synthase gene influences the progression of renal disease. Nephron 2002, 91(4):747-751.